- Current report filing (8-K)
December 18 2009 - 8:17AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
December
17, 2009
Date of
Report (date of earliest event reported)
(Exact
name of Registrant as specified in its charter)
Delaware
|
001-33382
|
33-0787406
|
(State or
other jurisdiction of
incorporation or
organization)
|
(Commission File
Number)
|
(I.R.S.
Employer
Identification
Number)
|
3
Morgan, Irvine, California 92618
(Address
of principal executive offices)
(949)
362-4800
(Registrant’s
telephone number, including area code)
N/A
(
Former name or former address, if
changed since last report
)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
8.01. Other Events.
On
December 17, 2009, a jury delivered a verdict in favor of SenoRx, Inc. (“SenoRx”
or the “Company”) in a lawsuit brought by Hologic, Inc., Cytyc Corp., and
Hologic L.P. (together “Hologic”) in the United States District Court, Northern
District of California. Hologic had alleged that SenoRx infringed
claims of Hologic’s 6,413,204 and 6,482,142 patents. SenoRx claimed that both
patents were invalid, and that the ‘204 patent was not infringed. The jury found
that SenoRx was not liable for infringement of the ‘204 patent and that both
patents were invalid. A copy of the press release announcing the
aforementioned verdict is furnished as Exhibit 99.1 to this Form 8-K and will be
available on our website at
www.senorx.com
.
Item 9.01. Financial
Statements and Exhibits.
(d)
Exhibits.
Exhibit No.
|
|
Description
|
99.1
|
|
Press
Release of SenoRx, Inc. dated as of December 18,
2009.
|
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
|
SENORX,
INC.
|
|
|
|
|
|
Date: December
18, 2009
|
By:
|
/s/ Kevin
J. Cousins
|
|
|
|
Kevin
J. Cousins
|
|
|
|
Chief
Financial Officer,
Vice President,
Finance
|
|
|
|
|
|
Senorx (MM) (NASDAQ:SENO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Senorx (MM) (NASDAQ:SENO)
Historical Stock Chart
From Oct 2023 to Oct 2024